The US Federal Trade Commission and Department of Justice should look at the past conduct of pharma companies seeking to merge, including their contracts with pharmacy benefit managers, and monitor the outcome of a merger on research and development, experts advised the agencies.
In the first day of a virtual two-day workshop on pharmaceutical mergers, panelists discussed factors the FTC should consider in analyzing mergers beyond traditional concerns about horizontal overlaps, and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?